GD-20

GD-20 is a small molecule drug candidate currently in preclinical development by Gudui BioPharma for the treatment of multiple sclerosis (MS). It is designed as a multi-target therapeutic, intended to simultaneously modulate several biological pathways involved in the neuroinflammatory and neurodegenerative processes of the disease. By addressing multiple targets, GD-20 aims to provide a more comprehensive therapeutic effect compared to traditional single-target agents, potentially improving outcomes for patients with MS. As of early 2024, the specific biological targets and detailed pharmacological profile remain proprietary to the developer.